ARCH Venture Management, LLC
Long book
$677.1M
Q1 2026
Positions
10
Top-10 weight
100%
concentration
Last quarter
+16.1%
SPY +14.8%
Turnover
10%
of book per quarter
Strategy in plain words
auto-generated from filingsARCH Venture Management, LLC is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $677.1M US long book across 10 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: MAZE THERAPEUTICS INC, RAPPORT THERAPEUTICS INC, VIR BIOTECHNOLOGY INC, ERASCA INC, BEAM THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 6.3pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+4.8%
Q2 2024
+3.5%
Q3 2024
-10.1%
Q4 2024
-29.9%
Q1 2025
-0.7%
Q2 2025
+72.9%
Q3 2025
+29.9%
Q4 2025
+10.2%
Q1 2026
+16.1%
Sector allocation
Healthcare 100%
Long book by quarter
What does ARCH Venture own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| MAZE MAZE THERAPEUTICS INC | Healthcare | 4.1M | $123.0M | 18.2% | Held |
| RAPP RAPPORT THERAPEUTICS INC | Healthcare | 3.7M | $116.7M | 17.2% | Held |
| VIR VIR BIOTECHNOLOGY INC | Healthcare | 12.9M | $115.7M | 17.1% | Held |
| ERAS ERASCA INC | Healthcare | 7.1M | $114.7M | 16.9% | -35.9% |
| BEAM BEAM THERAPEUTICS INC | Healthcare | 4.5M | $108.2M | 16.0% | Held |
| LYEL LYELL IMMUNOPHARMA INC | Healthcare | 3.2M | $65.1M | 9.6% | +17.7% |
| GENB GENERATE BIOMEDICINES INC | Healthcare | 1.9M | $24.3M | 3.6% | New |
| TXG 10X GENOMICS INC-CLASS A | Healthcare | 217.8K | $4.6M | 0.7% | -70.5% |
| GOSS GOSSAMER BIO INC | Healthcare | 8.1M | $2.6M | 0.4% | Held |
| QTTB Q32 BIO INC | Healthcare | 320.5K | $2.1M | 0.3% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 10 | $677.1M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 9 | $651.7M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 9 | $492.4M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 11 | $299.1M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 9 | $206.2M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 9 | $230.2M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 9 | $260.6M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 9 | $266.0M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 8 | $80.3M | canonical | SEC ↗ |